Poster Gavin Tan


Choroidal neovascularization (CNV) is rare but important cause of visual impairment in children. It is often idiopathic or secondary to inflammation, optic nerve head abnormalities or retinal dystrophies. There is a lack of clinical trials assessing the treatment of CNV in children.


A 11-year-old boy with no past medical or ocular history presented with 3 months duration of reduced vision in his left eye. Best-corrected visual acuity (BCVA) was 20/20 in the right eye and 20/80 in the left eye. Detailed examination including slit lamp biomicroscopy, fluorescein and indocyanine green angiography and spectral domain as well as swept source optical coherence tomography (OCT), revealed an active subfoveal type 2 CNV. Two consecutive monthly intravitreal bevacizumab injections (1.25mg/0.05ml) were given in the left eye.


There was resolution of subretinal fluid on OCT with improvement of left BCVA to 20/40. No ocular or systemic side effects were encountered. Our patient had unremarkable electrophysiology and investigations were normal except for a borderline positive toxoplasmosis IgG with no rise in IgG titer on repeated examination. Toxoplasmosis IgM was negative.


Intravitreal bevacizumab appears to be a potentially effective modality of treatment of CNV in children. Further studies are required to assess the safety and efficacy.